The Food and Drug Administration’s recent approval of new Alzheimer’s drugs sparked a flicker of hope for the millions affected by this devastating disease. But this progress casts a puzzling shadow.
The drugs come at a high cost for relatively limited benefits, offering only a brief respite in the pace of cognitive decline. This reality raises a question: Are we fixated on such marginally effective treatments at the expense of more promising preventive measures?
Let's start with the truth!
Support the Broken Science Initiative.
Subscribe today →
recent posts
Paradigm Shifts, Entrenched Thinking, and the Future of Medicine
A new paper proposes a single ratio, read off a fingerprick, that tells you where your metabolism is headed. It started in a cancer clinic. Its authors think it belongs in every MetFix affiliate.
Mark Sisson separates longevity fads from the habits that consistently improve health and performance
